Search

Your search keyword '"Barta, Stefan K."' showing total 779 results
Start Over Author "Barta, Stefan K."
779 results on '"Barta, Stefan K."'

1. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study

Author

Grover, Natalie S., Annunzio, Kaitlin, Watkins, Marcus, Torka, Pallawi, Karmali, Reem, Anampa-Guzmán, Andrea, Oh, Timothy S., Reves, Heather, Tavakkoli, Montreh, Hansinger, Emily, Christian, Beth, Thomas, Colin, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Shouse, Geoffrey, Olszewski, Adam J., and Epperla, Narendranath

Published
2024
Full Text
View/download PDF

3. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

Author

Ghilardi, Guido, Fraietta, Joseph A., Gerson, James N., Van Deerlin, Vivianna M., Morrissette, Jennifer J. D., Caponetti, Gabriel C., Paruzzo, Luca, Harris, Jaryse C., Chong, Elise A., Susanibar Adaniya, Sandra P., Svoboda, Jakub, Nasta, Sunita D., Ugwuanyi, Ositadimma H., Landsburg, Daniel J., Fardella, Eugenio, Waxman, Adam J., Chong, Emeline R., Patel, Vrutti, Pajarillo, Raymone, Kulikovskaya, Irina, Lieberman, David B., Cohen, Adam D., Levine, Bruce L., Stadtmauer, Edward A., Frey, Noelle V., Vogl, Dan T., Hexner, Elizabeth O., Barta, Stefan K., Porter, David L., Garfall, Alfred L., Schuster, Stephen J., June, Carl H., and Ruella, Marco

Published
2024
Full Text
View/download PDF

5. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

Author

Zinzani, Pier Luigi, Izutsu, Koji, Mehta-Shah, Neha, Barta, Stefan K, Ishitsuka, Kenji, Córdoba, Raul, Kusumoto, Shigeru, Bachy, Emmanuel, Cwynarski, Kate, Gritti, Giuseppe, Prica, Anca, Jacobsen, Eric, Feldman, Tatyana, Guillermin, Yann, Ennishi, Daisuke, Yoon, Dok Hyun, Domenech, Eva Domingo, Zain, Jasmine, Wang, Jie, Kim, Jin Seok, Poel, Marjolein van der, Jin, Jin, Wu, Sutan, Chen, Yang, Moriyama, Takaya, Inoue, Ai, Nakajima, Keiko, and Horwitz, Steven M

Published
2024
Full Text
View/download PDF

6. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation

Author

Epperla, Narendranath, Huang, Ying, Cashen, Amanda F., Vaughn, John L., Hanel, Walter, Badar, Talha, Barta, Stefan K., Caimi, Paolo F., Sethi, Tarsheen K., Reddy, Nishitha, Karmali, Reem, Bello, Celeste, Chavez, Julio C., Kothari, Shalin K., Hernandez-Ilizaliturri, Francisco J., Svoboda, Jakub, Lansigan, Frederick, Glenn, Martha J., Cohen, Jonathon B., Sorge, Caryn, Christian, Beth, Herrera, Alex F., Hamadani, Mehdi, Costa, Luciano J., and Xavier, Ana C.

Published
2024
Full Text
View/download PDF

7. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Author

Goyal, Amrita, O'Leary, Daniel, Dabaja, Bouthaina, Weng, Wen-Kai, Zain, Jasmine, Cutler, Corey, Guitart, Joan, Kim, Youn H., Geskin, Larisa J., Hoppe, Richard T., Wilson, Lynn D., Beaven, Anne W., Horwitz, Steve, Allen, Pamela B., Barta, Stefan K., Bohjanen, Kimberly, Brammer, Jonathan E., Carter, Joi B., Comfere, Nneka, DeSimone, Jennifer A., Dusenbery, Kathryn, Duvic, Madeleine, Huen, Auris, Jagadeesh, Deepa, Kelsey, Chris R., Khodadoust, Michael S., Lechowicz, Mary Jo, Mehta-Shah, Neha, Moskowitz, Alison J., Olsen, Elise A., Poh, Christina, Pro, Barbara, Querfeld, Christiane, Sauter, Craig, Sokol, Lubomir, Sokumbi, Olayemi, Wilcox, Ryan A., Zic, John A., Hamadani, Mehdi, and Foss, Francine

Published
2024
Full Text
View/download PDF

9. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Author

Bhansali, Rahul S., Ellin, Fredrik, Relander, Thomas, Cao, Miao, Li, Wenrui, Long, Qi, Ganesan, Nivetha, Stuver, Robert, Horwitz, Steven M., Wudhikarn, Kitsada, Hwang, Steven R., Bennani, N. Nora, Chavez, Julio, Sokol, Lubomir, Saeed, Hayder, Duan, Frank, Porcu, Pierluigi, Pullarkat, Priyanka, Mehta-Shah, Neha, Zain, Jasmine M., Ruiz, Miguel, Brammer, Jonathan E., Prakash, Rishab, Iyer, Swaminathan P., Olszewski, Adam J., Major, Ajay, Riedell, Peter A., Smith, Sonali M., Goldin, Caroline, Haverkos, Bradley, Hu, Bei, Zhuang, Tony Z., Allen, Pamela B., Toama, Wael, Janakiram, Murali, Brooks, Taylor R., Jagadeesh, Deepa, Hariharan, Nisha, Goodman, Aaron M., Hartman, Gabrielle, Ghione, Paola, Fayyaz, Fatima, Rhodes, Joanna M., Chong, Elise A., Gerson, James N., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Jerkeman, Mats, and Barta, Stefan K.

Published
2024
Full Text
View/download PDF

10. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

Author

Karmali, Reem, Machhi, Rushad, Epperla, Narendranath, Shouse, Geoffrey, Romancik, Jason, Moyo, Tamara K., Kenkre, Vaishalee, Ollila, Thomas A., Fitzgerald, Lindsey, Hess, Brian, David, Kevin, Roy, Ishan, Zurko, Joanna, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Ferdman, Robert, Bhansali, Rahul S., Harris, Elyse I., Liu, Jieqi, Nizamuddin, Imran, Ma, Shuo, Moreira, Jonathan, Winter, Jane, Pro, Barbara, Stephens, Deborah M., Danilov, Alexey, Shah, Nirav N., Cohen, Jonathon B., Barta, Stefan K., Torka, Pallawi, and Gordon, Leo I.

Published
2024
Full Text
View/download PDF

11. Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy

Author

Bond, David A, Switchenko, Jeffrey M, Villa, Diego, Maddocks, Kami, Churnetski, Michael C, Gerrie, Alina S, Goyal, Subir, Shanmugasundaram, Krithika, Calzada, Oscar, Kolla, Bhaskar, Bachanova, Veronika, Gerson, James Nathan, Barta, Stefan K, Hill, Brian T, Sawalha, Yazeed, Martin, Peter, Maldonado, Edward, Gordon, Max J, Danilov, Alexey V, Grover, Natalie Sophia, Mathews, Stephanie P, Burkart, Madelyn, Karmali, Reem, Ghosh, Nilanjan, Park, Steven I, Epperla, Narendranath, Badar, Talha, Guo, Jin, Hamadani, Mehdi, Fenske, Timothy S, Malecek, Mary-Kate, Kahl, Brad S, Flowers, Christopher R, Blum, Kristie, and Cohen, Jonathon B

Subjects
Rare Diseases, Prevention, Hematology, Lymphoma, Cancer, Adult, Humans, Lymphoma, Mantle-Cell, Prognosis, Prospective Studies, Recurrence, Treatment Outcome
Abstract

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

Published
2021

12. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines

Author

Ghilardi, Guido, Paruzzo, Luca, Svoboda, Jakub, Chong, Elise A., Shestov, Alexander A., Chen, Linhui, Cohen, Ivan J., Gabrielli, Giulia, Nasta, Sunita D., Porazzi, Patrizia, Landsburg, Daniel J., Gerson, James N., Carter, Jordan, Barta, Stefan K., Yelton, Rebecca, Pajarillo, Raymone, Patel, Vrutti, White, Griffin, Ballard, Hatcher J., Weber, Elizabeth, Napier, Ellen, Chong, Emeline R., Fraietta, Joseph A., Garfall, Alfred L., Porter, David L., Milone, Michael C., O’Connor, Roderick, Schuster, Stephen J., and Ruella, Marco

Published
2024
Full Text
View/download PDF

14. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

Author

Epperla, Narendranath, Feng, Lei, Shah, Nirav N., Fitzgerald, Lindsey, Shah, Harsh, Stephens, Deborah M., Lee, Catherine J., Ollila, Thomas, Shouse, Geoffrey, Danilov, Alexey V., David, Kevin A., Torka, Pallawi, Hashmi, Hamza, Hess, Brian, Barta, Stefan K., Romancik, Jason T., Cohen, Jonathon B., Annunzio, Kaitlin, Kittai, Adam S., Reneau, John, Zurko, Joanna, Nizamuddin, Imran A., Winter, Jane N., Gordon, Leo I., Ma, Shuo, Patel, Romil, Nastoupil, Loretta, Ahmed, Sairah, and Karmali, Reem

Published
2023
Full Text
View/download PDF

15. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Author

Epperla, Narendranath, Welkie, Rina Li, Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem, Shea, Lauren, Anampa-Guzmán, Andrea, Oh, Timothy S., Reaves, Heather, Tavakkoli, Montreh, Lindsey, Kathryn, Greenwell, Irl Brian, Hansinger, Emily, Thomas, Colin, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Christian, Beth, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Herrera, Alex F., Grover, Natalie S., and Olszewski, Adam J.

Published
2023
Full Text
View/download PDF

17. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

Author

Aminov, Sarah, Giricz, Orsi, Melnekoff, David T., Sica, R. Alejandro, Polishchuk, Veronika, Papazoglu, Cristian, Yates, Bonnie, Wang, Hao-Wei, Sahu, Srabani, Wang, Yanhua, Gordon-Mitchell, Shanisha, Leshchenko, Violetta V., Schinke, Carolina, Pradhan, Kith, Aluri, Srinivas, Sohn, Moah, Barta, Stefan K., Agarwal, Beamon, Goldfinger, Mendel, Mantzaris, Ioannis, Shastri, Aditi, Matsui, William, Steidl, Ulrich, Brody, Joshua D., Shah, Nirali N., Parekh, Samir, and Verma, Amit

Subjects
United States. National Cancer Institute, Chromatin, T cells, RNA sequencing, Viral antibodies, Immunotherapy, Ethylenediaminetetraacetic acid, B cells, Acute lymphocytic leukemia -- Drug therapy -- Development and progression, Genetic transcription, Antibodies, Health care industry
Abstract

While therapies targeting CD19 by antibodies, chimeric antigen receptor T cells (CAR-T), and T cell engagers have improved the response rates in B cell malignancies, the emergence of resistant cell populations with low CD19 expression can lead to relapsed disease. We developed an in vitro model of adaptive resistance facilitated by chronic exposure of leukemia cells to a CD19 immunotoxin. Single-cell RNA-Seq (scRNA- Seq) showed an increase in transcriptionally distinct [CD19.sup.lo] populations among resistant cells. Mass cytometry demonstrated that CD22 was also decreased in these [CD19.sup.lo]-resistant cells. An assay for transposase- accessible chromatin with sequencing (ATAC-Seq) showed decreased chromatin accessibility at promoters of both CD19 and CD22 in the resistant cell populations. Combined loss of both CD19 and CD22 antigens was validated in samples from pediatric and young adult patients with B cell acute lymphoblastic leukemia (B-ALL) that relapsed after CD19 CAR-T-targeted therapy. Functionally, resistant cells were characterized by slower growth and lower basal levels of MEK activation. [CD19.sup.lo] resistant cells exhibited preserved B cell receptor signaling and were more sensitive to both Bruton's tyrosine kinase (BTK) and MEK inhibition. These data demonstrate that resistance to CD19 immunotherapies can result in decreased expression of both CD19 and CD22 and can result in dependency on BTK pathways., Introduction Although much progress has been made in the treatment of B cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory disease is an ongoing problem. The development of CD19 chimeric [...]

Published
2024
Full Text
View/download PDF

18. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Author

Gerson, James N., Handorf, Elizabeth, Villa, Diego, Gerrie, Alina S., Chapani, Parv, Li, Shaoying, Medeiros, L. Jeffrey, Wang, Michael, Cohen, Jonathon B., Churnetski, Michael, Hill, Brian T., Sawalha, Yazeed, Hernandez-Ilizaliturri, Francisco J., Kothari, Shalin, Vose, Julie M., Bast, Martin, Fenske, Timothy, Rao Gari, Swapna Narayana, Maddocks, Kami J., Bond, David, Bachanova, Veronika, Kolla, Bhaskar, Chavez, Julio, Shah, Bijal, Lansigan, Frederick, Burns, Timothy, Donovan, Alexandra M., Wagner-Johnston, Nina, Messmer, Marcus, Mehta, Amitkumar, Anderson, Jennifer K., Reddy, Nishitha, Kovach, Alexandra E., Landsburg, Daniel J., Glenn, Martha, Inwards, David J., Ristow, Kay, Karmali, Reem, Kaplan, Jason B., Caimi, Paolo F., Rajguru, Saurabh, Evens, Andrew, Klein, Andreas, Umyarova, Elvira, Pulluri, Bhargavi, Amengual, Jennifer E., Lue, Jennifer K., Diefenbach, Catherine, Fisher, Richard I., and Barta, Stefan K.

Published
2023
Full Text
View/download PDF

20. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Author

Bowers, Jackson T., Anna, Jacob, Bair, Steven M., Annunzio, Kaitlin, Epperla, Narendranath, Pullukkara, Jerrin Joy, Gaballa, Sameh, Spinner, Michael A., Li, Shuning, Messmer, Marcus R., Nguyen, Joseph, Ayers, Emily C., Wagner, Charlotte B., Hu, Boyu, Di, Mengyang, Huntington, Scott F., Furqan, Fateeha, Shah, Nirav N., Chen, Christina, Ballard, Hatcher J., Hughes, Mitchell E., Chong, Elise A., Nasta, Sunita D., Barta, Stefan K., Landsburg, Daniel J., and Svoboda, Jakub

Published
2023
Full Text
View/download PDF

21. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Karmali, Reem, Torka, Pallawi, Shea, Lauren, Oh, Timothy S., Anampa-Guzmán, Andrea, Reves, Heather, Tavakkoli, Montreh, Greenwell, Irl Brian, Hansinger, Emily, Umyarova, Elvira, Annunzio, Kaitlin, Sawalha, Yazeed, Christian, Beth, Thomas, Colin, Barta, Stefan K., Geethakumari, Praveen Ramakrishnan, Bartlett, Nancy L., Grover, Natalie S., and Olszewski, Adam J.

Published
2023
Full Text
View/download PDF

23. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells

Author

Landsburg, Daniel J., Nasta, Sunita D., Svoboda, Jakub, Gerson, James N., Schuster, Stephen J., Barta, Stefan K., Chong, Elise A., Difilippo, Heather, Weber, Elizabeth, Cunningham, Kathleen, Catania, Christopher, Garfall, Alfred L., Stadtmauer, Edward A., Frey, Noelle V., and Porter, David L.

Published
2023
Full Text
View/download PDF

24. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Author

Barta, Stefan K., Hamdan, Ayad, Boué, François, Delobel, Pierre, Galicier, Lionel, Coppo, Paul, Ghesquières, Hervé, Rubinstein, Paul G, Moore, Page C, Bimali, Milan, Lee, Jeanette Y, Rudek, Michelle A, Chadburn, Amy, Ratner, Lee, Henry, David H, Cesarman, Ethel, DeMarco, Camille E, Costagliola, Dominique, Taoufik, Yassine, Ramos, Juan Carlos, Sharon, Elad, Reid, Erin G, Ambinder, Richard F, Mitsuyasu, Ronald, Mounier, Nicolas, Besson, Caroline, and Noy, Ariela

Published
2023
Full Text
View/download PDF

25. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Author

Zurko, Joanna, Nizamuddin, Imran, Epperla, Narendranath, David, Kevin, Cohen, Jonathon B., Moyo, Tamara K., Ollila, Thomas, Hess, Brian, Roy, Ishan, Ferdman, Robert, Liu, Jieqi, Chowdhury, Sayan Mullick, Romancik, Jason, Bhansali, Rahul S., Harris, Elyse I., Sorrell, Mckenzie, Masel, Rebecca, Kittai, Adam S., Denlinger, Nathan, Sigmund, Audrey M., Fitzgerald, Lindsey, Galvez, Carlos, Ma, Shuo, Winter, Jane, Pro, Barbara, Gordon, Leo I., Danilov, Alexey, Stephens, Deborah, Shah, Nirav N., Kenkre, Vaishalee, Barta, Stefan K., Torka, Pallawi, Shouse, Geoffrey, and Karmali, Reem

Published
2023
Full Text
View/download PDF

26. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Author

Epperla, Narendranath, Switchenko, Jeffrey, Bachanova, Veronika, Gerson, James N., Barta, Stefan K., Gordon, Max J., Danilov, Alexey V., Grover, Natalie S., Mathews, Stephanie, Burkart, Madelyn, Karmali, Reem, Sawalha, Yazeed, Hill, Brian T., Ghosh, Nilanjan, Park, Steven I., Bond, David A., Hamadani, Mehdi, Fenske, Timothy S., Martin, Peter, Malecek, Mary-Kate, Kahl, Brad S., Flowers, Christopher R., Link, Brian K., Kaplan, Lawrence D., Inwards, David J., Feldman, Andrew L., Hsi, Eric D., Maddocks, Kami, Blum, Kristie A., Bartlett, Nancy L., Cerhan, James R., Leonard, John P., Habermann, Thomas M., Maurer, Matthew J., and Cohen, Jonathon B.

Published
2023
Full Text
View/download PDF

29. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

30. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

Author

Melody, Megan, primary, Epperla, Narendranath, additional, Shouse, Geoffrey, additional, Romancik, Jason, additional, Allen, Pamela, additional, Moyo, Tamara K., additional, Kenkre, Vaishalee, additional, Ollila, Thomas, additional, Fitzgerald, Lindsey, additional, Hess, Brian, additional, David, Kevin, additional, Herr, Megan M., additional, Odetola, Oluwatobi, additional, Lin, Adam, additional, Moreira, Jonathan, additional, Ma, Shuo, additional, Winter, Jane N., additional, Roy, Ishan, additional, Stephens, Deborah, additional, Danilov, Alexey, additional, Shah, Nirav N., additional, Barta, Stefan K., additional, Cortese, Matthew, additional, Cohen, Jonathon B., additional, Gordon, Leo I., additional, and Karmali, Reem, additional

Published
2024
Full Text
View/download PDF

33. Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

Author

Elghawy, Omar, Cao, Miao, Xu, Jason, Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Chong, Elise A., Schuster, Stephen J., Thomas, Colin J., Carter, Jordan S., Tavakkoli, Montreh, Ruella, Marco, and Barta, Stefan K.

Subjects
T-cell lymphoma, FLOW cytometry, BONE marrow, TUMOR markers, DISEASE prevalence, AGE distribution, FUNCTIONAL status, RETROSPECTIVE studies, MULTIVARIATE analysis, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, ANTIGENS, IMMUNOHISTOCHEMISTRY, GENE expression, STATISTICS, SURVIVAL analysis (Biometry), DATA analysis software, T helper cells
Abstract

Simple Summary: T-cell lymphomas are hematologic cancers that are difficult to manage due to their aggressive nature and poor response to traditional chemotherapies. Response rates are unpredictable even in the era of novel therapeutics, and there has yet to be a clinically validated cellular marker associated with response rates or treatment outcomes. CD5 is a cellular marker that has been associated with poor outcomes in other cancers but has not been well established in T-cell lymphoma. This study confirmed that CD5 has a high prevalence in T-cell lymphomas and is associated with poor prognostic markers such as advanced age, bone marrow involvement, and poor functional status. Additionally, CD5 was associated with inferior survival in T-follicular cell lymphoma and adult T-cell lymphoma. These results suggest that CD5 is associated with worse prognosis in T-cell lymphomas and may be a potential therapeutic target in future studies. Background: T-cell lymphomas (TCLs) are a group of heterogenous cancers with poor rates and duration of response. There remains a great challenge in risk stratification of these cancers. Cluster of differentiation (CD) 5 has shown prognostic implication in many subtypes of B-cell lymphoma; however, its role in TCLs is not known. Methods: We performed a single-institution retrospective analysis of newly diagnosed patients with TCL. CD5 positivity was determined based on positive results via immunohistochemistry and/or flow cytometry. We used univariate and multivariable analysis of biological factors to assess their association with survival outcomes. Results: A total of 194 patients with TCL spanning 14 subtypes were identified. CD5 positivity was noted in 63% of patients, with the highest proportion of CD5 expression in TFH TCL (93.9%), PTCL-NOS (82.9%), and ATLL (77.8%) (p = 0.00004). Older age at diagnosis (p = 0.001), stage III or IV disease (p = 0.05), and bone marrow involvement (p = 0.003) were also associated with CD5 expression. Complete response rates were numerically lower in patients with CD5+ TCL across all subtypes. OS/PFS was not statistically associated with CD5 status in the overall cohort; however there was significantly decreased OS in CD5+ TFH TCL (p = 0.04) and CD5+ ATLL (p = 0.04) patients. Conclusions: This study represents the first to examine CD5 expression as a prognostic biomarker for outcomes in TCL. The frequent expression of CD5 in the most common nodal TCL in the Western world underpins its potential as an attractive target for cellular therapies. Confirmation of these findings in a larger cohort and investigation of potential pathophysiological mechanisms explaining our observations are planned. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature.

Author

Silva, Genevieve S., Kim, Ellen J., Barta, Stefan K., and Chung, Jina

Subjects
REGULATORY T cells, DRUG side effects, T-cell lymphoma, LITERATURE reviews, IMMUNE checkpoint inhibitors, CUTANEOUS T-cell lymphoma
Abstract

Mogamulizumab is an anti-C–C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review. This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others. Mogamulizumab's ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Author

Diefenbach, Catherine S, Hong, Fangxin, Ambinder, Richard F, Cohen, Jonathon B, Robertson, Michael J, David, Kevin A, Advani, Ranjana H, Fenske, Timothy S, Barta, Stefan K, Palmisiano, Neil D, Svoboda, Jakub, Morgan, David S, Karmali, Reem, Sharon, Elad, Streicher, Howard, Kahl, Brad S, and Ansell, Stephen M

Published
2020
Full Text
View/download PDF

37. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma

Author

Ghilardi, Guido, primary, Williamson, Staci, additional, Pajarillo, Raymone, additional, Paruzzo, Luca, additional, Chen, Linhui, additional, Grady, Connor, additional, Doucette, Abigail, additional, Nemecek, Eneida, additional, Gabrielli, Giulia, additional, Barta, Stefan K., additional, Svoboda, Jakub, additional, Chong, Elise A., additional, Yelton, Rebecca, additional, Nasta, Sunita D., additional, Landsburg, Daniel J., additional, Ugwuanyi, Ositadimma, additional, Chen, Andy I., additional, Schachter, Levanto, additional, White, Griffin, additional, Ballard, Hatcher J., additional, Weber, Elizabeth, additional, Curley, Cara, additional, Porter, David L., additional, Garfall, Alfred L., additional, Hwang, Wei-Ting, additional, Guerra, Carmen E., additional, Maziarz, Richard T., additional, Schuster, Stephen J., additional, and Ruella, Marco, additional

Published
2024
Full Text
View/download PDF

38. Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia

Author

Chong, Elise A, primary, Kumashie, Kingsley Gideon, additional, Chong, Emeline R, additional, Fabrizio, Joseph, additional, Gupta, Aditi, additional, Svoboda, Jakub, additional, Barta, Stefan K, additional, Walsh, Kristy M, additional, Napier, Ellen B, additional, Lundberg, Rachel K, additional, Nasta, Sunita D, additional, Gerson, James N, additional, Landsburg, Daniel J, additional, Gonzalez, Joyce, additional, Gaano, Andrew, additional, Weirick, Madison E, additional, McAllister, Christopher M, additional, Awofolaju, Moses, additional, John, Gavin N, additional, Kammerman, Shane C, additional, Novacek, Josef, additional, Pajarillo, Raymone, additional, Lundgreen, Kendall A, additional, Tanenbaum, Nicole, additional, Gouma, Sigrid, additional, Drapeau, Elizabeth M, additional, Adamski, Sharon, additional, D’Andrea, Kurt, additional, Pattekar, Ajinkya, additional, Hicks, Amanda, additional, Korte, Scott, additional, Sharma, Harsh, additional, Herring, Sarah, additional, Williams, Justine C, additional, Hamilton, Jacob T, additional, Bates, Paul, additional, Hensley, Scott E, additional, Luning Prak, Eline T, additional, Greenplate, Allison R, additional, Wherry, E John, additional, Schuster, Stephen J, additional, Ruella, Marco, additional, and Vella, Laura A, additional

Published
2024
Full Text
View/download PDF

39. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma

Author

Chong, Elise A., primary, Chong, Emeline R., additional, Therwhanger, Dylan, additional, Nasta, Sunita D., additional, Landsburg, Daniel J., additional, Barta, Stefan K., additional, Svoboda, Jakub, additional, Gerson, James N., additional, Ghilardi, Guido, additional, Paruzzo, Luca, additional, Fraietta, Joseph A., additional, Weber, Elizabeth, additional, Stefano, Natalie, additional, Porter, David L., additional, Frey, Noelle V., additional, Garfall, Alfred L., additional, Ruella, Marco, additional, and Schuster, Stephen J., additional

Published
2024
Full Text
View/download PDF

40. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Author

Palomba, M. Lia, primary, Crombie, Jennifer L., additional, Nastoupil, Loretta J., additional, Andreadis, Charalambos, additional, Isufi, Iris, additional, Hunter, Brad, additional, Winter, Allison, additional, Hess, Brian T, additional, Barta, Stefan K., additional, Frigault, Matthew J., additional, Grover, Natalie, additional, Jain, Michael D., additional, Moyo, Tamara K., additional, Patel, Sagar S., additional, Pophali, Priyanka A., additional, Bernasconi, David, additional, Parrilla, Charimar Santiago, additional, Kitali, Amani, additional, Liu, Fei Fei, additional, Gharibo, Mecide, additional, and Pasquini, Marcelo C., additional

Published
2024
Full Text
View/download PDF

45. Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis

Author

Epperla, Narendranath, primary, Zhao, Qiuhong, additional, Moyo, Tamara, additional, Watkins, Marcus P., additional, Tavakkoli, Montreh, additional, Bello, Celeste, additional, Torka, Pallawi, additional, Reddy, Nishitha, additional, Thomas, Colin, additional, Annunzio, Kaitlin, additional, Christian, Beth, additional, Barta, Stefan K., additional, Shouse, Geoffrey, additional, Olszewski, Adam J., additional, and Bartlett, Nancy L., additional

Published
2024
Full Text
View/download PDF

46. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

Author

Ryu Tiger, Yun Kyoung, Jain, Salvia, Barta, Stefan K., Tolu, Seda, Estrella, Brian, Sawas, Ahmed, Lue, Jennifer K., Francescone, Mark M., Pro, Barbara, and Amengual, Jennifer E.

Subjects
T-cell lymphoma, HISTONE deacetylase inhibitors, PEMETREXED, FOLIC acid, T cells
Abstract

Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II study in patients with untreated or R/R mature T cell lymphomas (MTCL). Patients received pralatrexate 25 mg/m2 and romidepsin 12 mg/m2 every 2 weeks. Fourteen patients were evaluable for efficacy. Overall response rate was 35.7% with CR in 14.3% and disease control in 50%. The mDOR was 8.2 months, mPFS was 3.6 months, and mOS was 20.2 months. Gastrointestinal side effects were most common in up to 33%; there was only one hematologic toxicity of grade 3 anemia. Combining results of MTCL patients from the Phase I and II studies (N = 28), the ORR was 53.5% with CR in 21.4%, disease control in67.8%, and DOR of 7.2 months. The combination was safe however does not out-perform other combination strategies.Trial Registration: (NCT 01947140). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Targeted Therapies in the Treatment of Mantle Cell Lymphoma.

Author

Thomas, Colin J., Carvajal, Veronica, and Barta, Stefan K.

Subjects
THERAPEUTIC use of antineoplastic agents, NF-kappa B, HEMATOPOIETIC stem cell transplantation, RISK assessment, NON-Hodgkin's lymphoma, IMMUNOTHERAPY, TREATMENT effectiveness, CYTOTOXINS, PROTEIN-tyrosine kinases, ALGORITHMS, OVERALL survival
Abstract

Simple Summary: Discussed here is a review of the changing landscape in the treatment of mantle cell lymphoma (MCL) regarding the emergence and use of targeted therapy. Targeted therapy is the use of small molecules designed to interrupt specific mechanisms within the cancer cell to exert anti-tumor efficacy. Targeting such mechanisms relies upon our understanding of what makes a cancer cell malignant. MCL is a difficult-to-treat lymphoid cancer that relies heavily upon constitutive intracellular signaling, promoting its growth and survival. The mainstay of MCL treatment has been to treat it with cytotoxic chemotherapy; however, targeted therapies have allowed for improved treatment outcomes and continue to change the way we manage this disease. This review aims to describe what targeted therapies are being utilized in MCL treatment and their mechanisms of action, safety, and efficacy, as well as future directions for their use in MCL treatment. Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin's lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma primarily affects older patients and is frequently chemotherapy-resistant, which has further fostered the necessity for new, chemotherapy-free treatment options. In the past decade, targeted therapies in mantle cell lymphoma have been practice-changing as the treatment paradigm shifts further away from relying primarily on cytotoxic agents. Here, we will review the pathophysiology of mantle cell lymphoma and discuss the emergence of targeted, chemotherapy-free treatments aimed at disrupting the abnormal biology driving its lymphomagenesis. Treatments targeting the constitutive activation of NF-kB, Bruton's Tyrosine Kinase signaling, and anti-apoptosis will be the primary focus as we discuss their clinical data and toxicities. Our review will also focus primarily on the emergence and use of targeted therapies in the relapsed/refractory setting but will also discuss the emergence of their use in front-line therapy and in combination with other agents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Bendamustine Lymphodepletion Before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines

Author

Ghilardi, Guido, primary, Paruzzo, Luca, additional, Svoboda, Jakub, additional, Chong, Elise A., additional, Shestov, Alexander A, additional, Chen, Linhui, additional, Cohen, Ivan J, additional, Gabrielli, Giulia, additional, Nasta, Sunita D., additional, Porazzi, Patrizia, additional, Landsburg, Daniel J., additional, Gerson, James N., additional, Carter, Jordan, additional, Barta, Stefan K., additional, Yelton, Rebecca Dawn, additional, Pajarillo, Raymone, additional, Patel, Vrutti, additional, White, Griffin, additional, Ballard, Hatcher, additional, Weber, Elizabeth, additional, Napier, Ellen B, additional, Chong, Emeline R, additional, Fraietta, Joseph A., additional, Garfall, Alfred, additional, Porter, David L., additional, Milone, Michael C, additional, O'Connor, Roddy S, additional, Schuster, Stephen J., additional, and Ruella, Marco, additional

Published
2023
Full Text
View/download PDF

50. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study

Author

Annunzio, Kaitlin, primary, Grover, Natalie S., additional, Welkie, Rina Li, additional, Torka, Pallawi, additional, Watkins, Marcus P., additional, Anampa-Guzmán, Andrea, additional, Tavakkoli, Montreh, additional, Oh, Timothy S., additional, Reves, Heather, additional, Jones, Daniel, additional, Hanel, Walter, additional, Christian, Beth, additional, Ramakrishnan Geethakumari, Praveen, additional, Karmali, Reem, additional, Barta, Stefan K., additional, Bartlett, Nancy L., additional, Olszewski, Adam J., additional, and Epperla, Narendranath, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results